Fangdie Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fangdie Ye has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Jing Zhang
Division of Basic Biomedical Sciences, The University of South Dakota Sanford School of Medicine, Vermillion, SD 57069, USA
3 shared publicationsLisa Jia Tran
Department of General, Visceral, And Transplant Surgery, Ludwig-Maximilians-University Munich, Bayern, Munich 81377, Germany
3 shared publications- Zhou Sun
Department of Urology China‐Japan Union Hospital of Jilin University Changchun People's Republic of China
3 shared publications Baoluo Ma
Department of Urology, Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang Hubei China
2 shared publicationsJie Wang
Department of Urology, The Second People’s Hospital of Meishan, Meishan, Sichuan 620500, China
2 shared publicationsYingchun Liang
Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
Engineered hollow Prussian blue nanoparticles for synergistic anti-inflammatory therapy in sepsis
- 28 August 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
Open AccessEngineered hollow Prussian blue nanoparticles for synergistic anti-inflammatory therapy in sepsis
- Open Access
- 25 August 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy
- 25 August 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
Open AccessAn engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy
- Open Access
- 5 August 2026
- Published by Springer Nature in npj Digital Medicine
Policy optimized MedGemma for multimodal prostate cancer care
- 5 August 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessPolicy optimized MedGemma for multimodal prostate cancer care
- 23 March 2024
- Published by Springer Nature in Cellular Oncology
- Vol. 47 (4) , 1375-1389
DNA hypomethylation patterns and their impact on the tumor microenvironment in colorectal cancer
Background Recent research underscores the pivotal role of immune checkpoints as biomarkers in colorectal cancer (CRC) therapy, highlighting the dynamics of resistance and response to immune checkpoint inhibitors. The impact of epigenetic alterations in CRC, particularly in relation to immune therapy resistance, is not fully understood. Methods We integrated a comprehensive dataset encompassing TCGA-COAD, TCGA-READ, and multiple GEO series (GSE14333, GSE37892, GSE41258), along with key epigenetic datasets (TCGA-COAD, TCGA-READ, GSE77718). Hierarchical clustering, based on Euclidean distance and Ward's method, was applied to 330 primary tumor samples to identify distinct clusters. The immune microenvironment was assessed using MCPcounter. Machine learning algorithms were employed to predict DNA methylation patterns and their functional enrichment, in addition to transcriptome expression analysis. Genomic mutation profiles and treatment response assessments were also conducted. Results Our analysis delineated a specific tumor cluster with CpG Island (CGI) methylation, termed the Demethylated Phenotype (DMP). DMP was associated with metabolic pathways such as oxidative phosphorylation, implicating increased ATP production efficiency in mitochondria, which contributes to tumor aggressiveness. Furthermore, DMP showed activation of the Myc target pathway, known for tumor immune suppression, and exhibited downregulation in key immune-related pathways, suggesting a tumor microenvironment characterized by diminished immunity and increased fibroblast infiltration. Six potential therapeutic agents—lapatinib, RDEA119, WH.4.023, MG.132, PD.0325901, and AZ628—were identified as effective for the DMP subtype. Conclusion This study unveils a novel epigenetic phenotype in CRC linked to resistance against immune checkpoint inhibitors, presenting a significant step toward personalized medicine by suggesting epigenetic classifications as a means to identify ideal candidates for immunotherapy in CRC. Our findings also highlight potential therapeutic agents for the DMP subtype, offering new avenues for tailored CRC treatment strategies.
- 23 March 2024
- Published by Springer Nature in Cellular Oncology
- Vol. 47 (4) , 1375-1389
DNA hypomethylation patterns and their impact on the tumor microenvironment in colorectal cancer
Background Recent research underscores the pivotal role of immune checkpoints as biomarkers in colorectal cancer (CRC) therapy, highlighting the dynamics of resistance and response to immune checkpoint inhibitors. The impact of epigenetic alterations in CRC, particularly in relation to immune therapy resistance, is not fully understood. Methods We integrated a comprehensive dataset encompassing TCGA-COAD, TCGA-READ, and multiple GEO series (GSE14333, GSE37892, GSE41258), along with key epigenetic datasets (TCGA-COAD, TCGA-READ, GSE77718). Hierarchical clustering, based on Euclidean distance and Ward's method, was applied to 330 primary tumor samples to identify distinct clusters. The immune microenvironment was assessed using MCPcounter. Machine learning algorithms were employed to predict DNA methylation patterns and their functional enrichment, in addition to transcriptome expression analysis. Genomic mutation profiles and treatment response assessments were also conducted. Results Our analysis delineated a specific tumor cluster with CpG Island (CGI) methylation, termed the Demethylated Phenotype (DMP). DMP was associated with metabolic pathways such as oxidative phosphorylation, implicating increased ATP production efficiency in mitochondria, which contributes to tumor aggressiveness. Furthermore, DMP showed activation of the Myc target pathway, known for tumor immune suppression, and exhibited downregulation in key immune-related pathways, suggesting a tumor microenvironment characterized by diminished immunity and increased fibroblast infiltration. Six potential therapeutic agents—lapatinib, RDEA119, WH.4.023, MG.132, PD.0325901, and AZ628—were identified as effective for the DMP subtype. Conclusion This study unveils a novel epigenetic phenotype in CRC linked to resistance against immune checkpoint inhibitors, presenting a significant step toward personalized medicine by suggesting epigenetic classifications as a means to identify ideal candidates for immunotherapy in CRC. Our findings also highlight potential therapeutic agents for the DMP subtype, offering new avenues for tailored CRC treatment strategies.
- Open Access
- 6 November 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (21) , 12104-12119
Collaborating single-cell and bulk RNA sequencing for comprehensive characterization of the intratumor heterogeneity and prognostic model development for bladder cancer
Introduction: Gaining a deeper insight into the single-cell RNA sequencing (scRNA-seq) results of bladder cancer (BLCA) provides a transcriptomic profiling of individual cancer cells, which may disclose the molecular mechanisms involved in BLCA carcinogenesis. Methods: scRNA data were obtained from GSE169379 dataset. We used the InferCNV software to determine the copy number variant (CNV) with normal epithelial cells serving as the reference, and performed the pseudo-timing analysis on subsets of epithelial cell using Monocle3 software. Transcription factor analysis was conducted using the Dorothea software. Intercellular communication analysis was performed using the Liana software. Cox analysis and LASSO regression were applied to establish a prognostic model. Results: We investigated the heterogeneity of tumors in four distinct cell types of BLCA cancer, namely immune cells, endothelial cells, epithelial cells, and fibroblasts. We evaluated the transcription factor activity of different immune cells in BLCA and identified significant enrichment of TCF7 and TBX21 in CD8+ T cells. Additionally, we identified two distinct subtypes of cancer-associated fibroblasts (CAFs), namely iCAFs and myoCAFs, which exhibited distinct communication patterns. Using sub-cluster and cell trajectory analyses, we identified different states of normal-to-malignant cell transformation in epithelial cells. TF analysis further revealed high activation of MYC and SOX2 in tumor cells. Finally, we identified five model genes (SLCO3A1, ANXA1, TENM3, EHBP1, LSAMP) for the development of a prognostic model, which demonstrated high effectiveness in stratifying patients across seven different cohorts. Conclusions: We have developed a prognostic model that has demonstrated significant efficacy in stratifying patients with BLCA.
- 6 November 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (21) , 12104-12119
Open AccessCollaborating single-cell and bulk RNA sequencing for comprehensive characterization of the intratumor heterogeneity and prognostic model development for bladder cancer
Introduction: Gaining a deeper insight into the single-cell RNA sequencing (scRNA-seq) results of bladder cancer (BLCA) provides a transcriptomic profiling of individual cancer cells, which may disclose the molecular mechanisms involved in BLCA carcinogenesis. Methods: scRNA data were obtained from GSE169379 dataset. We used the InferCNV software to determine the copy number variant (CNV) with normal epithelial cells serving as the reference, and performed the pseudo-timing analysis on subsets of epithelial cell using Monocle3 software. Transcription factor analysis was conducted using the Dorothea software. Intercellular communication analysis was performed using the Liana software. Cox analysis and LASSO regression were applied to establish a prognostic model. Results: We investigated the heterogeneity of tumors in four distinct cell types of BLCA cancer, namely immune cells, endothelial cells, epithelial cells, and fibroblasts. We evaluated the transcription factor activity of different immune cells in BLCA and identified significant enrichment of TCF7 and TBX21 in CD8+ T cells. Additionally, we identified two distinct subtypes of cancer-associated fibroblasts (CAFs), namely iCAFs and myoCAFs, which exhibited distinct communication patterns. Using sub-cluster and cell trajectory analyses, we identified different states of normal-to-malignant cell transformation in epithelial cells. TF analysis further revealed high activation of MYC and SOX2 in tumor cells. Finally, we identified five model genes (SLCO3A1, ANXA1, TENM3, EHBP1, LSAMP) for the development of a prognostic model, which demonstrated high effectiveness in stratifying patients across seven different cohorts. Conclusions: We have developed a prognostic model that has demonstrated significant efficacy in stratifying patients with BLCA.
- 27 October 2023
- Published by Wiley in Environmental Toxicology
- Vol. 39 (2) , 869-881
The single‐cell evolution trajectory presented different hypoxia heterogeneity to reveal the carcinogenesis of genes in clear cell renal cell carcinoma: Based on multiple omics and real experimental verification
Introduction: Clear cell renal cell carcinoma (ccRCC) is the most prevalent and aggressive subtype of renal cell carcinoma, originating from renal tubular epithelial cells in the kidney. Hypoxia proves to be a feature commonly observed in solid tumors, leading to increased resistance to treatment and tumor progression.Methods: scRNA‐seq data were procured from GSE159115 data set. We utilized UMAP and NMF algorithm for clustering and dimensionality reduction. The FindAllMarkers function was used to compare various groups and identify potential hypoxia marker genes. A series of in vitro experiments, including CFA, flow cytometry targeting cell cycle, CCK‐8, and EDU, was applied to investigate how ANGPTL4 regulated the ccRCC progression. Two cell lines of ccRCC cells, 786‐O and Caki, were used for si‐ANGPTL4 transfection.Results: We annotated a total of a total of 6 cell clusters, namely ccRCC malignant cells, T cells, endothelial cells, myeloid cells, smooth muscle cells, and B cells. We observed higher levels of hypoxia‐score in the ccRCC malignant cells, while lowest hypoxia‐score in T and B cells. We detected multiple hypoxia‐related subclusters of TME cells in ccRCC, among which S100A4 CD8+ T cells and nonhypoxia CD8+ T cells were found with a marked elevation of T cell inhibitory gene score. We identified that ANGPTL4+ endothelial cells might function as an integrative role in tumor angiogenesis. Multiple TME subclusters showed high potency in stratification of the prognosis of ccRCC patients. Moreover, by a series of in vitro experiment, we found ANGPTL4 regulated the ccRCC cell proliferation, probably through ERK/P38 pathway.Conclusion: We discerned multiple hypoxia‐related subclusters of TME cells in ccRCC, which displayed distinct functional features and great potency in predicting prognosis of ccRCC patients. We identified the role of ANGPTL4 in regulating ccRCC proliferation via ERK/p38 pathway.
- 27 October 2023
- Published by Wiley in Environmental Toxicology
- Vol. 39 (2) , 869-881
The single‐cell evolution trajectory presented different hypoxia heterogeneity to reveal the carcinogenesis of genes in clear cell renal cell carcinoma: Based on multiple omics and real experimental verification
Introduction: Clear cell renal cell carcinoma (ccRCC) is the most prevalent and aggressive subtype of renal cell carcinoma, originating from renal tubular epithelial cells in the kidney. Hypoxia proves to be a feature commonly observed in solid tumors, leading to increased resistance to treatment and tumor progression.Methods: scRNA‐seq data were procured from GSE159115 data set. We utilized UMAP and NMF algorithm for clustering and dimensionality reduction. The FindAllMarkers function was used to compare various groups and identify potential hypoxia marker genes. A series of in vitro experiments, including CFA, flow cytometry targeting cell cycle, CCK‐8, and EDU, was applied to investigate how ANGPTL4 regulated the ccRCC progression. Two cell lines of ccRCC cells, 786‐O and Caki, were used for si‐ANGPTL4 transfection.Results: We annotated a total of a total of 6 cell clusters, namely ccRCC malignant cells, T cells, endothelial cells, myeloid cells, smooth muscle cells, and B cells. We observed higher levels of hypoxia‐score in the ccRCC malignant cells, while lowest hypoxia‐score in T and B cells. We detected multiple hypoxia‐related subclusters of TME cells in ccRCC, among which S100A4 CD8+ T cells and nonhypoxia CD8+ T cells were found with a marked elevation of T cell inhibitory gene score. We identified that ANGPTL4+ endothelial cells might function as an integrative role in tumor angiogenesis. Multiple TME subclusters showed high potency in stratification of the prognosis of ccRCC patients. Moreover, by a series of in vitro experiment, we found ANGPTL4 regulated the ccRCC cell proliferation, probably through ERK/P38 pathway.Conclusion: We discerned multiple hypoxia‐related subclusters of TME cells in ccRCC, which displayed distinct functional features and great potency in predicting prognosis of ccRCC patients. We identified the role of ANGPTL4 in regulating ccRCC proliferation via ERK/p38 pathway.
- Open Access
- 10 October 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-15
Exploring oncogenes for renal clear cell carcinoma based on G protein-coupled receptor-associated genes
G protein-coupled receptors (GPCRs) are a class of receptors on cell membranes that regulate various biological processes in cells, such as cell proliferation, differentiation, migration, apoptosis, and metabolism, by interacting with G proteins. However, the role of G protein-coupled receptors in predicting the prognosis of renal clear cell carcinoma is still unknown. The transcriptome data and clinical profiles of renal clear cell carcinoma patients, were downloaded from TCGA databases, and the validation group data were downloaded from number GSE167573, including 63 tumor samples and 14 normal samples. Single-cell RNA sequencing data were downloaded from the GEO database, No. GSE152938 and selected samples were used for GSEA enrichment analysis, WGCNA subgroup analysis, single-cell data analysis, and mutation analysis to explore the role of G protein-coupled receptor-related genes in the diagnosis and prognosis of renal clear cell carcinoma and to verify their reliability with cellular experiments. Finally, this study establishes a disease model based on G protein-coupled receptor-related genes, which may help to propose targeted therapeutic regimens in different strata of renal cell carcinoma patients.Author names: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author: Given name [Lisa Jia] Last name [Tran].It's ok!
- 10 October 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-15
Open AccessExploring oncogenes for renal clear cell carcinoma based on G protein-coupled receptor-associated genes
G protein-coupled receptors (GPCRs) are a class of receptors on cell membranes that regulate various biological processes in cells, such as cell proliferation, differentiation, migration, apoptosis, and metabolism, by interacting with G proteins. However, the role of G protein-coupled receptors in predicting the prognosis of renal clear cell carcinoma is still unknown. The transcriptome data and clinical profiles of renal clear cell carcinoma patients, were downloaded from TCGA databases, and the validation group data were downloaded from number GSE167573, including 63 tumor samples and 14 normal samples. Single-cell RNA sequencing data were downloaded from the GEO database, No. GSE152938 and selected samples were used for GSEA enrichment analysis, WGCNA subgroup analysis, single-cell data analysis, and mutation analysis to explore the role of G protein-coupled receptor-related genes in the diagnosis and prognosis of renal clear cell carcinoma and to verify their reliability with cellular experiments. Finally, this study establishes a disease model based on G protein-coupled receptor-related genes, which may help to propose targeted therapeutic regimens in different strata of renal cell carcinoma patients.Author names: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author: Given name [Lisa Jia] Last name [Tran].It's ok!
- 11 August 2023
- Published by Wiley in Environmental Toxicology
- Vol. 39 (2) , 657-668
Coordinating single‐cell and bulk RNA‐seq in deciphering the intratumoral immune landscape and prognostic stratification of prostate cancer patients
Introduction: Prostate cancer is a common cancer among male population. The aberrant expression of histone modifiers has been identified as a potential driving force in numerous cancer types. However, the mechanism of histone modifiers in the development of prostate cancer remains unknown.Methods: Expression profiles and clinical data were obtained from GSE70769, GSE46602, and GSE67980. Seruat R package was utilized to calculate the gene set enrichment of the histone modification pathway and obtain the Histone score. Least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were employed to identify marker genes with prognostic value. Kaplan–Meier survival analysis was conducted to assess the efficacy of the prognostic model. In addition, microenvironment cell populations counter (MCPcounter), single‐sample gene set enrichment analysis (ssGSEA), and xCell algorithms were employed for immune infiltration analysis. Drug sensitivity prediction was performed using oncoPredict R package.Results: We screened differentially expressed genes (DEGs) between Histone‐high score (Histone‐H) and Histone‐low score (Histone‐L) groups, which were enriched in RNA splicing and DNA‐binding transcription factor binding pathways. We retained four prognostic marker genes, including TACC3, YWHAH, TAF1C and TTLL5. The risk model showed significant efficacy in stratification of the prognosis of prostate cancer patients in both internal and external cohorts (p < .0001 and p = .032, respectively). In addition, prognostic gene YWHAH was infiltrated in abundance of fibroblasts and highly correlated with Entinostat_1593 drug sensitivity score and the value of risk score.Conclusion: We innovatively developed a histone modification‐related prognostic model with high prognostic potency and identified YWHAH as possible diagnostic and therapeutic biomarkers for prostate cancer. It provides novel insights to address prostate cancer and enhance clinical outcomes, thereby opening up a new avenue for customized treatment alternatives.
- 11 August 2023
- Published by Wiley in Environmental Toxicology
- Vol. 39 (2) , 657-668
Coordinating single‐cell and bulk RNA‐seq in deciphering the intratumoral immune landscape and prognostic stratification of prostate cancer patients
Introduction: Prostate cancer is a common cancer among male population. The aberrant expression of histone modifiers has been identified as a potential driving force in numerous cancer types. However, the mechanism of histone modifiers in the development of prostate cancer remains unknown.Methods: Expression profiles and clinical data were obtained from GSE70769, GSE46602, and GSE67980. Seruat R package was utilized to calculate the gene set enrichment of the histone modification pathway and obtain the Histone score. Least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were employed to identify marker genes with prognostic value. Kaplan–Meier survival analysis was conducted to assess the efficacy of the prognostic model. In addition, microenvironment cell populations counter (MCPcounter), single‐sample gene set enrichment analysis (ssGSEA), and xCell algorithms were employed for immune infiltration analysis. Drug sensitivity prediction was performed using oncoPredict R package.Results: We screened differentially expressed genes (DEGs) between Histone‐high score (Histone‐H) and Histone‐low score (Histone‐L) groups, which were enriched in RNA splicing and DNA‐binding transcription factor binding pathways. We retained four prognostic marker genes, including TACC3, YWHAH, TAF1C and TTLL5. The risk model showed significant efficacy in stratification of the prognosis of prostate cancer patients in both internal and external cohorts (p < .0001 and p = .032, respectively). In addition, prognostic gene YWHAH was infiltrated in abundance of fibroblasts and highly correlated with Entinostat_1593 drug sensitivity score and the value of risk score.Conclusion: We innovatively developed a histone modification‐related prognostic model with high prognostic potency and identified YWHAH as possible diagnostic and therapeutic biomarkers for prostate cancer. It provides novel insights to address prostate cancer and enhance clinical outcomes, thereby opening up a new avenue for customized treatment alternatives.
- Open Access
- 12 March 2021
- Published by Springer Nature in Research Square
Emerging biomarker associated with prognosis of prostate cancer identified via co-expression analysis
Background: Forkhead box protein f1 (Foxf1) is associated with oncogenesis, and maybe play a key role in prostate cancer. However, the effect of Foxf1 on the development of prostate cancer and its clinical implications were still unknown. Method: The transcriptome data and clinical information were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). The differential co-expression genes which were the most closely correlated with prostate cancer were identified by weighted gene co-expression network analysis (WGCNA) and differential expression analysis method. The univariate cox regressions were performed to identify the prognostic genes. Finally, Foxf1 were verified in clinical tumor samples and matched normal tissues. Results: A total of 108 differential co-expression genes were identified. Foxf1 was identified that significantly associated with overall survival rate and biochemical recurrence of prostate. Then, protein-protein interaction (PPI) networks were constructed, including 21 nodes and 26 edges. The data revealed GAPVD1, MIR522, MIR937, CPS1, HOXB9, FUBP3, MIR936, SDF4, SATB2, HOXB13, MIR375, PUSL1, SATB1, MIR382, MIR429, HOXD13, PRSS50, FLNC, STRBP, KHSRP were significant associated with the regulation and function of differentially expressed Foxf1 in prostate. The experimental results confirmed the Foxf1 were downregulated in the prostate cancer tissues compared with the matched normal tissues.Conclusion: we obtained a gene Foxf1 which is significantly related with the prognosis of prostate cancer, Foxf1 have significant values in predicting the patients’ Overall survival and may serve as a potential prognosis biomarker and a new therapeutic target of prostate cancer.
- 12 March 2021
- Published by Springer Nature in Research Square
Open AccessEmerging biomarker associated with prognosis of prostate cancer identified via co-expression analysis
Background: Forkhead box protein f1 (Foxf1) is associated with oncogenesis, and maybe play a key role in prostate cancer. However, the effect of Foxf1 on the development of prostate cancer and its clinical implications were still unknown. Method: The transcriptome data and clinical information were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). The differential co-expression genes which were the most closely correlated with prostate cancer were identified by weighted gene co-expression network analysis (WGCNA) and differential expression analysis method. The univariate cox regressions were performed to identify the prognostic genes. Finally, Foxf1 were verified in clinical tumor samples and matched normal tissues. Results: A total of 108 differential co-expression genes were identified. Foxf1 was identified that significantly associated with overall survival rate and biochemical recurrence of prostate. Then, protein-protein interaction (PPI) networks were constructed, including 21 nodes and 26 edges. The data revealed GAPVD1, MIR522, MIR937, CPS1, HOXB9, FUBP3, MIR936, SDF4, SATB2, HOXB13, MIR375, PUSL1, SATB1, MIR382, MIR429, HOXD13, PRSS50, FLNC, STRBP, KHSRP were significant associated with the regulation and function of differentially expressed Foxf1 in prostate. The experimental results confirmed the Foxf1 were downregulated in the prostate cancer tissues compared with the matched normal tissues.Conclusion: we obtained a gene Foxf1 which is significantly related with the prognosis of prostate cancer, Foxf1 have significant values in predicting the patients’ Overall survival and may serve as a potential prognosis biomarker and a new therapeutic target of prostate cancer.